Lataa...
The predictive value of tumor mutation burden for immune checkpoint inhibitors therapy in non-small cell lung cancer is affected by patients’ age
High tumor mutation burden (TMB), which is associated with increased tumor immunogenicity, has been identified to predict improved response to immune checkpoint inhibitors (ICIs) therapy in non-small cell lung cancer (NSCLC). As host immunity is also significant to eliminate cancer cells, however, i...
Tallennettuna:
| Julkaisussa: | Biomark Res |
|---|---|
| Päätekijät: | , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
BioMed Central
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7146978/ https://ncbi.nlm.nih.gov/pubmed/32308981 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40364-020-00188-2 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|